'The “pooled fund” is designed to reduce the high costs of developing new treatments. It would do so partly by increasing the number of experimental drugs being tested, raising the chances that some will succeed. It would also reduce the risks of unsuccessful new products by bringing in capital from non-profit backers who do not seek financial returns.'

https://www.ft.com/content/2f939fbd-06ee-46c5-a956-800266d5dd86